Peptides for Weight Loss: A Comprehensive Guide
For an investigational approach outside the incretin pathway, see our eloralintide evidence guide, which distinguishes the amylin agonist from the separate EloraTZP combination.
Peptides for weight loss: approved medicines, meaningful trial results, current investigational findings, related nonpeptides and practical safety distinctions.
The landscape: molecule, product and indication matter
Peptides are chains of amino acids. Some peptide medicines have strong obesity-trial evidence and approved uses; others are investigational or marketed without comparable clinical validation. Semaglutide, tirzepatide and liraglutide are not interchangeable products or doses. Wegovy, Zepbound and Saxenda have weight-management indications; Ozempic and Mounjaro have diabetes-focused indications and additional benefits in specified populations. Some semaglutide products are oral, so peptide treatment does not always mean an injection.
GLP-1 receptor agonism can reduce appetite and calorie intake, affect glucose-dependent insulin secretion and delay gastric emptying. Tirzepatide also acts at GIP receptors. These effects do not establish a universal increase in resting metabolism, selective fat burning or guaranteed results. Treatment choice depends on the actual product and person, rather than the number of receptors or a peptide label.
What the established trials show
STEP 1 studied 1,961 adults without diabetes: semaglutide 2.4 mg weekly produced mean weight change of −14.9% versus −2.4% with placebo at 68 weeks, with lifestyle support. SURMOUNT-1 studied 2,539 adults without diabetes: tirzepatide 5/10/15 mg produced −15.0/−19.5/−20.9% versus −3.1% at 72 weeks under the treatment-regimen analysis. Different analyses must be identified; 22.5% should not replace the 20.9% result without context. These separate trials are not a direct ranking.
SURMOUNT-5 directly compared maximum tolerated tirzepatide 10/15 mg with semaglutide 1.7/2.4 mg in 751 adults with obesity without diabetes: −20.2% versus −13.7% at 72 weeks. It did not test semaglutide 7.2 mg or all current products. SCALE found 8.4 kg versus 2.8 kg loss with liraglutide 3 mg versus placebo at 56 weeks; kilograms are not percentages. STEP 1; SURMOUNT-1; SURMOUNT-5; SCALE.
Benefits can extend beyond weight. SELECT found major cardiovascular events in 6.5% versus 8.0% with semaglutide versus placebo in adults with established cardiovascular disease and overweight/obesity without diabetes: a 20% relative reduction over mean follow-up of about 40 months. This is meaningful evidence for that population, not proof of universal longevity benefit. SELECT.
Approved schedules and oral options
Wegovy injection is weekly, Zepbound weekly and Saxenda daily, with product-specific gradual escalation and maintenance rules. Starting doses are not automatically long-term maintenance doses. Current Wegovy labeling includes oral tablets and a 7.2 mg injection option for certain adults after appropriate prior treatment; 2.4 mg is not its only current option. Rybelsus and Ozempic tablets have their own indications and administration, with strengths that are not interchangeable milligram for milligram.
Foundayo (orforglipron) is an approved oral GLP-1 receptor agonist and a nonpeptide small molecule. It is relevant to the treatment landscape but should not be called an investigational peptide. Prescribed dose and device instructions matter; a reconstitution or syringe-unit calculator does not establish a suitable medicine, concentration or regimen. Approved ready-to-use products should not be reconstituted according to a research-vial protocol. Wegovy label; Zepbound label; Saxenda label; Foundayo label.
Investigational peptides: preserve the promise and the limits
Retatrutide activates GIP, GLP-1 and glucagon receptors and remains investigational. Its earlier phase 2 trial reported up to 24.2% mean loss at 48 weeks versus 2.1% with placebo, an encouraging finding that motivated larger studies. Published TRIUMPH-1 treatment-regimen results at 80 weeks were −25.0% at 12 mg versus −3.9% with placebo. The sponsor’s 28.3% figure used an efficacy analysis; both are useful when labeled correctly. A positive trial is not FDA approval, a personal forecast or a consumer titration protocol. Lilly has described a planned Q1 2027 submission, rather than a completed approval or guaranteed launch. TRIUMPH-1.
Survodutide is a GLP-1/glucagon dual agonist with current phase 3 findings. SYNCHRONIZE-1 reported 76-week treatment-regimen changes of −12.2% and −13.0% at 3.6/6.0 mg versus −5.4% with placebo in people without diabetes; the sponsor’s larger efficacy estimate is a different analysis. Different trial populations and estimands matter; its obesity and liver-disease findings remain research evidence, without a US approved retail product. Other research combinations may also offer benefits, but comparisons should use actual trials rather than select the largest number from unrelated studies. FDA states retatrutide and cagrilintide cannot be used in compounding under federal law. FDA current statement.
AOD-9604, secretagogues and related nonpeptides
AOD-9604 is a modified growth-hormone fragment, not a growth-hormone-releasing secretagogue. Animal fat-metabolism findings motivated human research. A company-affiliated report summarized oral and intravenous tolerability without an increase in IGF-1; that is useful safety research within its limits, not validation of injected weight-loss treatment. FDA’s 2024 briefing describes the larger oral OPTIONS study’s unsuccessful weight-loss endpoint and the lack of identified human subcutaneous exposure data. The oral OPTIONS findings do not establish a successful injected obesity treatment. Human report; FDA evidence briefing.
CJC-1295 and ipamorelin are studied around the growth-hormone axis, but hormone increases do not establish safe, sustained obesity treatment or additional benefit when stacked with GLP-1 medicines. MK-677 (ibutamoren), 5-amino-1MQ, tesofensine and orforglipron are nonpeptide molecules often grouped into this marketing category. Their mechanisms, human evidence and regulatory status differ. Tesofensine’s small 203-person randomized phase 2 study reported 9.2 percentage points more loss than diet/placebo at 0.5 mg over 24 weeks, alongside increased heart rate; it has no FDA-approved obesity use. These findings are an interesting research signal, rather than evidence of equivalence to a GLP-1 medicine. Original tesofensine trial. Neither a research label nor an absence of large human trials supplies a validated obesity regimen.
Safety, monitoring and realistic maintenance
Read the actual medicine’s contraindications and warnings. Gastrointestinal effects are common, but no single 15–45% rate describes all symptoms and products. Current Wegovy, Zepbound and Saxenda labels contraindicate use with personal/family medullary thyroid carcinoma or MEN2. A history of pancreatitis is a clinical consideration rather than the same universal formal contraindication. Pregnancy plans, other medicines, gallbladder disease, severe digestive symptoms, dehydration and procedures requiring anesthesia need review. The earlier suicidal-ideation warning has been removed from current Wegovy, Zepbound and Saxenda labeling.
Persistent severe abdominal pain, inability to keep fluids down or allergic breathing difficulty needs prompt care. Do not overlap GLP-1 medicines or add a research-peptide stack yourself. Nutrition and resistance activity support health and muscle function, with protein individualized to needs and restrictions; lean mass is not synonymous with skeletal muscle. A calorie, hydration or protein target is not universal.
Obesity care often includes long-term treatment and follow-up. In an exploratory STEP 1 extension, the semaglutide group regained 11.6 percentage points one year after a 17.3% loss when medication and structured lifestyle support ended, remaining 5.6% below baseline. That is not a personal guarantee or proof that a low starting dose prevents regain. Original extension.
Costs, access and choosing the next question
Compare the actual prescribed product, pharmacy price, insurance coverage and total cost of clinical care. Manufacturer savings or patient-assistance programs can be useful for eligible people, but terms, exclusions, duration and application requirements matter. A list price is not everyone’s payment, and no fixed $0–250 copay, income threshold or future generic discount applies to everyone. Ask the treating team about a covered alternative when cost blocks care; switching depends on the indication and clinical circumstances. Our GLP-1 Program Guide provides a framework to compare online care programs and included support.
Coverage depends on the plan, service and indication. Check current coverage rules and program eligibility rather than assume all obesity prescriptions are covered. A compound is not an FDA-approved generic, and current requirements address individual medical need and restrictions on copies. Retatrutide has no approved commercial prescription price.
Ask which product and outcome fit your health goals, what evidence supports it, what follow-up is needed, how nutrition and function will be supported, and the actual ongoing total cost. Useful emerging research can be followed without self-prescribing an investigational product or treating every marketing category as an approved medicine.
| Compound | Relevant status | Key distinction |
|---|---|---|
| Semaglutide | Approved product-specific uses | Oral and injectable formulations, different doses and indications. |
| Tirzepatide | Approved product-specific uses | Weight-management and diabetes brands differ. |
| Liraglutide | Approved product-specific uses | Daily injection; weight-management and diabetes brands differ. |
| Retatrutide | Investigational | Positive phase 3 evidence is not FDA approval or an available retail prescription. |
| AOD-9604 | Not an approved obesity medicine | Preclinical and limited-route human evidence does not validate subcutaneous weight loss. |
Frequently Asked Questions
There is no universal best. In the direct SURMOUNT-5 trial, tirzepatide produced greater mean loss than the studied semaglutide doses, but the trial did not compare every current option. Indication, safety, response, tolerability, preferences and access matter.
Trial averages depend on dose, analysis, population and duration. STEP 1 found −14.9% with semaglutide 2.4 mg versus −2.4% at 68 weeks; SURMOUNT-1 found −20.9% at tirzepatide 15 mg versus −3.1% at 72 weeks under the treatment-regimen analysis. These are not individual forecasts or a head-to-head comparison.
Approved products have evaluated benefits and risks for their labeled uses; that does not make them risk-free or suitable for everyone. Gastrointestinal effects and specific contraindications/warnings matter. Research products have different evidence and uncertainty, and a clinician should assess the actual treatment.
Regain is common but varies. In the 327-person STEP 1 exploratory extension, the semaglutide group regained 11.6 percentage points one year after a 17.3% loss when medication and structured lifestyle support ended. Ongoing care and maintenance decisions should be individualized.
Approved prescription medicines require an appropriate prescription. Research-only products and peptide supplements are not equivalent. Patient-specific compounding has separate requirements and is not a blanket prescription-free or low-cost generic alternative.
Both use semaglutide, but formulations, devices, doses and approved uses differ. Wegovy includes oral and injectable weight-management products and other specific indications; Ozempic has diabetes-focused indications and oral as well as injectable products. Do not substitute milligram for milligram or assume all semaglutide brands are identical.
GLP-1 receptor agonism affects appetite, calorie intake, gastric emptying and glucose-dependent signaling. Tirzepatide also acts at GIP receptors. Those mechanisms do not guarantee a fixed metabolic-rate increase, selective fat loss or a particular personal result.
AOD-9604 has animal and limited oral/intravenous human research, but its larger oral weight-loss trial was unsuccessful and injected obesity efficacy is not established. CJC-1295 and ipamorelin are not validated substitutes for approved obesity treatments. Some related marketed compounds, including MK-677 and 5-amino-1MQ, are not peptides.